<DOC>
	<DOCNO>NCT00000635</DOCNO>
	<brief_summary>To determine safety , effectiveness , toxicity topical ( local ) trifluridine treat mucocutaneous ( nasal , oral , vaginal , anal opening ) Herpes simplex virus ( HSV ) disease show resistance acyclovir HIV-infected patient . HSV infection patient AIDS often associate skin sore frequent recurrence . Treatment drug acyclovir result heal patient , repeat treatment sometimes result resistance virus acyclovir . Thus , happen , treatment need use . Trifluridine antiviral drug use treatment Herpes infection occur eye . This study attempt determine trifluridine useful treat HSV sore heal treatment acyclovir .</brief_summary>
	<brief_title>Treatment Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease Patients With AIDS : Open Label Pilot Study Topical Trifluridine</brief_title>
	<detailed_description>HSV infection patient AIDS often associate skin sore frequent recurrence . Treatment drug acyclovir result heal patient , repeat treatment sometimes result resistance virus acyclovir . Thus , happen , treatment need use . Trifluridine antiviral drug use treatment Herpes infection occur eye . This study attempt determine trifluridine useful treat HSV sore heal treatment acyclovir . Patients receive least 10 day ( 42 day ) treatment topical trifluridine . Trifluridine apply thin fluid layer overlap edge lesion . Polymyxin B sulfate/bacitracin zinc ointment apply trifluridine . Lesions cover nonabsorbent dressing . Medication apply every 8 hour .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<mesh_term>Polymyxin B</mesh_term>
	<mesh_term>Polymyxins</mesh_term>
	<mesh_term>Bacitracin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Included : All medication deem essential best patient care , include zidovudine ( AZT ) , Pneumocystis carinii pneumonia ( PCP ) prophylaxis , acute maintenance therapy opportunistic infection . Patients must follow : HIV infection diagnosis AIDS . Mucocutaneous Herpes simplex virus infection . Ability give inform consent . Allowed : Patients may coenrolled ACTG study except treatment expect generate neutropenia . Subjects age 13 17 may enrol appropriate consent parent guardian . Exclusion Criteria Concurrent Medication : Excluded : Acyclovir , ganciclovir , foscarnet , vidarabine investigational drug potential antiHerpes simplex virus activity . Patients follow exclude : Previous hypersensitivity reaction trifluridine , polymyxin B bacitracin . Prior Medication : Excluded : Immunomodulators , lymphocyte replacement therapy biologic response modifier within 14 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Bacitracin</keyword>
	<keyword>Polymyxin B</keyword>
	<keyword>Trifluridine</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Herpesviridae Infections</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Anti-Infective Agents , Local</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>